Technetium-99m NM 01 diagnostic - Lantheus Holdings/NanoMab
Alternative Names: [99mTc]-NM01; NM 01 - NanoMab/Lantheus HoldingsLatest Information Update: 22 Sep 2023
At a glance
- Originator NanoMab
- Developer Lantheus Holdings; NanoMab
- Class Antibodies; Antibody diagnostics; Imaging agents; Radiopharmaceutical diagnostics; Technetium compounds
- Mechanism of Action Single-photon emission-computed tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Non-small cell lung cancer
Most Recent Events
- 29 Mar 2023 Preclinical trials in Non-small cell lung cancer in USA (unspecified route)(Lantheus Holdings Pipeline, March 2023)